NPS Reports Successful GATTEX(TM) Extension Study (The San Francisco Examiner)
BEDMINSTER, N.J. ( Map ) - BEDMINSTER, N.J., March 17 /PRNewswire-FirstCall/ — NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) today reported positive top-line results from a 28-week blinded Phase 3-extension study of GATTEX(TM) (teduglutide) for short bowel syndrome (SBS) patients who are dependent upon parenteral nutrition (PN). The extension study enrolled 65 of the 71 patients (91%) who had …